Estia Health Limited operates residential aged care homes in Australia.
Undervalued with questionable track record.
Share Price & News
How has Estia Health's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 26E's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: 26E underperformed the German Healthcare industry which returned -24.1% over the past year.
Return vs Market: 26E underperformed the German Market which returned -20.9% over the past year.
Price Volatility Vs. Market
How volatile is Estia Health's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Estia Health undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 26E (€0.68) is trading below our estimate of fair value (€16.7)
Significantly Below Fair Value: 26E is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 26E is good value based on its PE Ratio (9.3x) compared to the Healthcare industry average (27.4x).
PE vs Market: 26E is good value based on its PE Ratio (9.3x) compared to the German market (16.6x).
Price to Earnings Growth Ratio
PEG Ratio: 26E's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: 26E is good value based on its PB Ratio (0.4x) compared to the DE Healthcare industry average (1.1x).
How is Estia Health forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 26E's earnings are forecast to decline over the next 3 years (-2.2% per year).
Earnings vs Market: 26E's earnings are forecast to decline over the next 3 years (-2.2% per year).
High Growth Earnings: 26E's earnings are forecast to decline over the next 3 years.
Revenue vs Market: 26E's revenue (5% per year) is forecast to grow faster than the German market (3.9% per year).
High Growth Revenue: 26E's revenue (5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 26E's Return on Equity is forecast to be low in 3 years time (3.9%).
How has Estia Health performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 26E has high quality earnings.
Growing Profit Margin: 26E's current net profit margins (5.6%) are lower than last year (7.4%).
Past Earnings Growth Analysis
Earnings Trend: 26E has become profitable over the past 5 years, growing earnings by 36.6% per year.
Accelerating Growth: 26E's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 26E had negative earnings growth (-17.8%) over the past year, making it difficult to compare to the Healthcare industry average (26%).
Return on Equity
High ROE: 26E's Return on Equity (4.6%) is considered low.
How is Estia Health's financial position?
Financial Position Analysis
Short Term Liabilities: 26E's short term assets (A$43.5M) do not cover its short term liabilities (A$950.4M).
Long Term Liabilities: 26E's short term assets (A$43.5M) do not cover its long term liabilities (A$291.8M).
Debt to Equity History and Analysis
Debt Level: 26E's debt to equity ratio (15.4%) is considered satisfactory.
Reducing Debt: 26E's debt to equity ratio has increased from 0.1% to 15.4% over the past 5 years.
Debt Coverage: 26E's debt is well covered by operating cash flow (86.7%).
Interest Coverage: 26E's interest payments on its debt are not well covered by EBIT (2.9x coverage).
Inventory Level: 26E has a high level of physical assets or inventory.
Debt Coverage by Assets: 26E's debt is not covered by short term assets (assets are 0.4x debt).
What is Estia Health's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 26E's dividend (12.85%) is higher than the bottom 25% of dividend payers in the German market (1.71%).
High Dividend: 26E's dividend (12.85%) is in the top 25% of dividend payers in the German market (4.85%)
Stability and Growth of Payments
Stable Dividend: 26E has been paying a dividend for less than 10 years and during this time payments have been volatile.
Growing Dividend: 26E's dividend payments have increased, but the company has only paid a dividend for 5 years.
Current Payout to Shareholders
Dividend Coverage: With its high payout ratio (99.7%), 26E's dividend payments are not well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: 26E's dividends in 3 years are not forecast to be well covered by earnings (97.9% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Ian Thorley is Chief Executive Officer and Managing Director at Estia Health Limited since November 23, 2018. Mr. Thorley was the Chief Operating Officer of Estia Health Limited since October 24, 2016 ...
CEO Compensation Analysis
Compensation vs Market: Ian's total compensation ($USD467.59K) is below average for companies of similar size in the German market ($USD744.69K).
Compensation vs Earnings: Ian's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
|MD, CEO & Director||1.42yrs||AU$778.12k||0.053% A$94.5k|
|Chief Financial Officer||3.17yrs||AU$540.13k||0.0063% A$11.3k|
|COO & Deputy CEO||1.5yrs||AU$760.06k||no data|
|Chief Information Officer||2.5yrs||no data||no data|
|General Counsel||5.33yrs||no data||no data|
|Chief People Officer||2.75yrs||no data||no data|
|Chief Policy & Regulatory Officer||3.33yrs||no data||no data|
|Chief Customer Officer||2.5yrs||no data||no data|
|Chief Quality & Risk Officer||0.92yr||no data||no data|
|Company Secretary||1yr||no data||no data|
Experienced Management: 26E's management team is considered experienced (2.5 years average tenure).
|MD, CEO & Director||1.42yrs||AU$778.12k||0.053% A$94.5k|
|Non-Executive Director||4.17yrs||AU$135.00k||0.0092% A$16.5k|
|Non-Executive Chairman||4.25yrs||AU$280.00k||0.018% A$33.1k|
|Independent Director||5.42yrs||AU$1.16m||0.050% A$88.7k|
|Non-Executive Director||2.75yrs||AU$125.00k||0.019% A$34.3k|
|Non-Executive Director||2.92yrs||AU$125.00k||0.045% A$80.2k|
|Independent Director||1.5yrs||AU$87.16k||0.012% A$22.2k|
Experienced Board: 26E's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: 26E insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Estia Health Limited's company bio, employee growth, exchange listings and data sources
- Name: Estia Health Limited
- Ticker: 26E
- Exchange: DB
- Founded: 2005
- Industry: Health Care Facilities
- Sector: Healthcare
- Market Cap: AU$321.364m
- Listing Market Cap: AU$178.999m
- Shares outstanding: 261.27m
- Website: https://www.estiahealth.com.au
Number of Employees
- Estia Health Limited
- 227 Elizabeth Street
- Level 9
- New South Wales
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|EHE||ASX (Australian Securities Exchange)||Yes||Ordinary Shares||AU||AUD||Dec 2014|
|EHE||CHIA (Chi-X Australia)||Yes||Ordinary Shares||AU||AUD||Dec 2014|
|26E||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Dec 2014|
Estia Health Limited operates residential aged care homes in Australia. It has 69 homes that comprise 6,180 operating bed licenses in Victoria, South Australia, New South Wales, and Queensland. The company was founded in 2005 and is based in Sydney, Australia.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/04/04 21:52|
|End of Day Share Price||2020/04/03 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.